Joining Novartis in siRNA space, AstraZeneca hands Silence $80M upfront for discovery deal
Mene Pangalos is doubling down on RNA-based technologies for his side of the AstraZeneca R&D machine.
Just two months after bringing a small activating RNA (saRNA) program into its fold, Pangalos now has his eyes on Silence Therapeutics’ small interfering RNA (siRNA) platform. Calling it an “exciting new modality” for the pharma giant’s drug discovery toolbox, AstraZeneca has shelled out $60 million in cash and purchased $20 million worth of Silence’s stock on the London exchange.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.